The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $44.08

Today's change-0.05 -0.11%
Updated April 25 11:04 AM EDT. Delayed by at least 15 minutes.
 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $44.08

Today's change-0.05 -0.11%
Updated April 25 11:04 AM EDT. Delayed by at least 15 minutes.

Abbott Laboratories down (U.S.)$0.05

Abbott Laboratories is lower today, dropping (U.S.)$0.05 or 0.11% to (U.S.)$44.08. Over the last five days, shares have gained 1.50% and are currently 3.84% off of the 52-week high. Shares have underperformed the S&P 500 by 14.17% during the last year.

Key company metrics

  • Open(U.S.) $44.21
  • Previous close(U.S.) $44.13
  • High(U.S.) $44.39
  • Low(U.S.) $43.99
  • Bid / Ask(U.S.) $44.08 / (U.S.) $44.09
  • YTD % change+14.76%
  • Volume1,684,101
  • Average volume (10-day)7,717,211
  • Average volume (1-month)6,702,889
  • Average volume (3-month)8,314,805
  • 52-week range(U.S.) $36.76 to (U.S.) $45.84
  • Beta1.43
  • Trailing P/E48.94×
  • P/E 1 year forward17.86×
  • Forward PEG1.59×
  • Indicated annual dividend(U.S.) $1.06
  • Dividend yield2.40%
  • Trailing EPS(U.S.) $0.90
Updated April 25 11:04 AM EDT. Delayed by at least 15 minutes.
S&P TSX0.37%Sector:HealthcareIndustry:Pharmaceuticals - Diversified

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue6,3355,3335,3025,333
Total other revenue--------
Total revenue6,3355,3335,3025,333
Gross profit3,2913,0233,0173,052
Total cost of revenue3,0442,3102,2852,281
Total operating expense6,5374,3854,4054,517
Selling / general / administrative2,4241,6061,6181,746
Research & development547338352348
Depreciation / amortization522121140145
Interest expense (income), net operating--------
Unusual expense (income)--1010-3
Other operating expenses, total--------
Operating income-202948897816
Interest income (expense), net non-operating-204-153-117-103
Gain (loss) on sale of assets--------
Other--------
Income before tax736875-179715
Income after tax386765-357599
Income tax, total350110178116
Net income419798-329615
Total adjustments to net income--------
Net income before extra. items386765-357599
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items386765-357599
Inc. avail. to common incl. extra. items419798-329615
Diluted net income419798-329615
Dilution adjustment----00
Diluted weighted average shares1,7351,4841,4761,480
Diluted EPS excluding extraordinary itemsvalue per share0.220.52-0.240.40
Dividends per sharevalue per share0.270.260.260.26
Diluted normalized EPSvalue per share0.220.52-0.240.40